Navlimetostat

DRUG4 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol-Myers Squibb, M.D. Anderson Cancer Center

Conditions

Advanced and/or Metastatic Solid Tumors with Homozygous MTAP DeletionHealthy ParticipantsNon-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 1

A Phase 1 Study of Navlimetostat Tablet Formulations

RecruitingNCT07544628

Bristol-Myers SquibbHealthy Participants

Start: 2026-04-27End: 2026-10-15Target: 64Updated: 2026-06-24

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Not yet recruitingNCT07579221

M.D. Anderson Cancer CenterNon-Small Cell Lung Cancer

Start: 2026-11-30End: 2031-08-01Target: 17Updated: 2026-06-05

Phase 2

A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

Active, not recruitingNCT07076121

Bristol-Myers SquibbPancreatic Ductal Adenocarcinoma

Start: 2025-10-23End: 2029-05-03Target: 470Updated: 2026-06-03

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Not yet recruitingCTIS2025-524285-18-00

Bristol-Myers Squibb Services Unlimited CompanyAdvanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Target: 67Updated: 2026-07-08

Related Papers

A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): MountainTAP-30.

Journal of Clinical Oncology2026-01-10